Biogen, Genentech amend deal on MS drug

Discuss Ocrelizumab, a monoclonal antibody treatment for MS.
Post Reply
User avatar
MSUK
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm
Contact:

Biogen, Genentech amend deal on MS drug

Post by MSUK » Thu Oct 21, 2010 10:45 pm

Image

Biogen Idec Inc. and Genentech said Thursday they amended their development agreement on a potential multiple sclerosis treatment.
Genentech, a unit of Swiss drug developer Roche, will now have responsibility for the further development of ocrelizumab in multiple sclerosis and will fund all the costs going forward.

Biogen will receive tiered, double-digit royalties on U.S. sales that will approximate its current 30 percent interest in the compound........... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397
MS-UK - http://www.ms-uk.org/

Post Reply
  • Similar Topics
    Replies
    Views
    Last post